Back to Search
Start Over
Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study.
- Source :
-
Radiotherapy & Oncology . Jun2024, Vol. 195, pN.PAG-N.PAG. 1p. - Publication Year :
- 2024
-
Abstract
- • Optimal dose and fractionation in SBRT for oligometastatic cancer patients remain unknown. • In the first 1,099 OligoCare patients, median number of fractions was 5 and fraction dose 9.7 Gy. • On multivariate analysis, dose varied significantly for primary cancer type and metastatic sites. • Future analysis will address safety and efficacy of this site- and disease-adapted SBRT practice. Optimal dose and fractionation in stereotactic body radiotherapy (SBRT) for oligometastatic cancer patients remain unknown. In this interim analysis of OligoCare, we analyzed factors associated with SBRT dose and fractionation. Analysis was based on the first 1,099 registered patients. SBRT doses were converted to biological effective doses (BED) using α/β of 10 Gy for all primaries, and cancer-specific α/β of 10 Gy for non-small cell lung and colorectal cancer (NSCLC, CRC), 2.5 Gy for breast cancer (BC), or 1.5 Gy for prostate cancer (PC). Of the interim analysis population of 1,099 patients, 999 (99.5 %) fulfilled inclusion criteria and received metastasis-directed SBRT for NSCLC (n = 195; 19.5 %), BC (n = 163; 16.3 %), CRC (n = 184; 18.4 %), or PC (n = 457; 47.5 %). Two thirds of patients were treated for single metastasis. Median number of fractions was 5 (IQR, 3–5) and median dose per fraction was 9.7 (IQR, 7.7–12.4) Gy. The most frequently treated sites were non-vertebral bone (22.8 %), lung (21.0 %), and distant lymph node metastases (19.0 %). On multivariate analysis, the dose varied significantly for primary cancer type (BC: 237.3 Gy BED, PC 300.6 Gy BED, and CRC 84.3 Gy BED), and metastatic sites, with higher doses for lung and liver lesions. This real-world analysis suggests that SBRT doses are adjusted to the primary cancers and oligometastasis location. Future analysis will address safety and efficacy of this site- and disease-adapted SBRT fractionation approach (NCT03818503). [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 01678140
- Volume :
- 195
- Database :
- Academic Search Index
- Journal :
- Radiotherapy & Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 177222757
- Full Text :
- https://doi.org/10.1016/j.radonc.2024.110235